WINNERS & LOSERS: Next climbs; Ceres jumps on Centrica deal
(Alliance News) - The following are the leading risers and fallers among FTSE 100 and 250 index constituents on Thursday. Read More
| Price | 2,047.00p on 26-03-2026 at 19:40:06 |
|---|---|
| Change | -7.00p -0.34% |
| Buy | 2,045.00p |
| Sell | 2,044.00p |
| Last Trade: | Buy 179.00 at 2,047.00p |
| Day's Volume: | 12,704,366 |
| Last Close: | 2,047.00p |
| Open: | 2,035.00p |
| ISIN: | GB00BN7SWP63 |
| Day's Range | 2,035.00p - 2,072.00p |
| 52wk Range: | 1,242.50p - 2,282.00p |
| Market Capitalisation: | £81.86b |
| VWAP: | 2,046.59261p |
| Shares in Issue: | 4.00b |
Glaxosmithkline (GSK) Latest Trades |
||||
| Buy/Sell | Volume | Trade Prc | Trade Type | Trade Time |
|---|---|---|---|---|
| Buy* | 179 | 2,047.00p | SI Trade Negotiated Trade |
16:50:41 - 26-Mar-26 |
| Buy* | 12,305 | 2,047.00p | SI Trade |
16:36:30 - 26-Mar-26 |
| Buy* | 142 | 2,047.00p | SI Trade |
16:36:30 - 26-Mar-26 |
| Buy* | 22,311 | 2,047.00p | SI Trade |
16:35:09 - 26-Mar-26 |
| Buy* | 255 | 2,047.00p | SI Trade |
16:35:09 - 26-Mar-26 |
| Buy* | 93 | 2,047.00p | SI Trade |
16:35:09 - 26-Mar-26 |
| Buy* | 1,680 | 2,047.00p | SI Trade |
16:35:09 - 26-Mar-26 |
| Buy* | 28 | 2,047.00p | SI Trade |
16:35:09 - 26-Mar-26 |
| Buy* | 280 | 2,047.00p | SI Trade |
16:35:09 - 26-Mar-26 |
| Buy* | 133 | 2,047.00p | SI Trade |
16:35:09 - 26-Mar-26 |
Glaxosmithkline (GSK) Regulatory News |
||
| Date | Source | Headline |
|---|---|---|
| 25th Mar 2026 3:30 pm | RNS | Director/PDMR Shareholding |
| 25th Mar 2026 1:00 pm | RNS | Notice of AGM |
| 25th Mar 2026 7:00 am | RNS | Transaction in Own Shares |
| 24th Mar 2026 7:00 am | RNS | Transaction in Own Shares |
| 23rd Mar 2026 3:30 pm | RNS | Director/PDMR Shareholding |
| 23rd Mar 2026 3:00 pm | RNS | Admission to Trading |
| 23rd Mar 2026 7:00 am | RNS | GSK Lung Cancer ADC Gets Japan Orphan Drug Status |
| 23rd Mar 2026 7:00 am | RNS | Transaction in Own Shares |
| 20th Mar 2026 7:00 am | RNS | Transaction in Own Shares |
| 19th Mar 2026 12:00 pm | RNS | Lynavoy (linerixibat) approved by US FDA |